Lumida
/UPB
⌘K
Upstream Bio Inc

Upstream Bio Inc

UPB
$5.73USD-0.35%-0.02 today

MARKET CAP

313.8M

P/E (TTM)

FWD P/E

DAY RANGE

$6 – $6

52W RANGE

$6
$34

AI Summary

Stalk
Sell NowMedium

UPB remains entrenched in a Stage 4 decline with price trading below its key moving averages. Medium-term bias is bearish, reinforced by a series of lower highs and lower lows and dynamic resistance at the 9/21 EMAs. Despite extreme oversold readings, recent rallies into EMAs have been rejected, supporting a Sell Now posture. A break and hold above the 21 EMA would invalidate this bearish timing edge.

  • Q2 2026 revenue $0.77M up 82.7% YoY, beat estimates by 15.4%
  • EPS loss narrowed to $0.73 vs $0.78 estimate
  • Q2 2026 net loss of $39.7M with negative earnings yield
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$2.4M$2.9M
YoY %+20.4%
P / Sales94.9x512.3x
EV / Sales-37.6x481.6x
Gross Profit, Adj.$2.4M$2.9M
YoY %+20.4%
Margin %100.0%100.0%
EV / Gross Profit-37.6x481.6x
EBITDA, Adj.$-77.7M$-160.2M
YoY %-106.2%
Margin %-3277.4%-5612.2%
EV / EBITDA1.1x-8.6x
EBIT$-77.8M$-160.4M
YoY %-106.2%
Margin %-3281.2%-5618.8%
EV / EBIT1.1x-8.6x
Net Income$-76.4M$-143.4M
YoY %-87.8%
Net Margin-3223.4%-5026.0%
EPS (GAAP)-$5.58-$2.66
YoY %+52.3%